ROIVANT SCIENCES LTD. Financing Cash Flow
ROIVANT SCIENCES LTD. (ROIV) reported Financing Cash Flow of -$181.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$181.51M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$68.78M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $328.19M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $62.59M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2026 was $134.24M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2025 was -$1.22B, a 390.87% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2024 was $419.36M, a 16.04% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2023 was $499.46M, a 62.80% increase from fiscal 2022.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$181.51M 10-Q · filed 2026-08-06 | -$250.29M derived: sum of 2 quarters · filed 2026-08-06 | $77.91M derived: sum of 3 quarters · filed 2026-08-06 | $140.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$68.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $259.42M derived: sum of 2 quarters · filed 2026-05-20 | $322.00M derived: sum of 3 quarters · filed 2026-05-20 | $134.24M 10-K · filed 2026-05-20 |
| 2025-12-31 | $328.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $390.78M derived: sum of 2 quarters · filed 2026-02-06 | $203.01M 10-Q · filed 2026-02-06 | $25.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $62.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$125.18M 10-Q · filed 2025-11-10 | -$302.33M derived: sum of 3 quarters · filed 2026-08-06 | -$575.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$187.77M 10-Q · filed 2026-08-06 | -$364.92M derived: sum of 2 quarters · filed 2026-08-06 | -$637.87M derived: sum of 3 quarters · filed 2026-08-06 | -$746.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$177.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$450.10M derived: sum of 2 quarters · filed 2026-05-20 | -$559.18M derived: sum of 3 quarters · filed 2026-05-20 | -$1.22B 10-K · filed 2026-05-20 |
| 2024-12-31 | -$272.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$382.02M derived: sum of 2 quarters · filed 2026-02-06 | -$1.04B 10-Q · filed 2026-02-06 | -$1.08B derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$109.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$769.69M 10-Q · filed 2025-11-10 | -$802.31M derived: sum of 3 quarters · filed 2026-05-20 | -$565.67M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$660.62M 10-Q · filed 2025-08-11 | -$693.24M derived: sum of 2 quarters · filed 2026-05-20 | -$456.60M derived: sum of 3 quarters · filed 2026-05-20 | -$248.73M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$32.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $204.01M derived: sum of 2 quarters · filed 2026-05-20 | $411.89M derived: sum of 3 quarters · filed 2026-05-20 | $419.36M 10-K · filed 2026-05-20 |
| 2023-12-31 | $236.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $444.51M derived: sum of 2 quarters · filed 2025-02-10 | $451.99M 10-Q · filed 2025-02-10 | $662.32M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $207.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $215.35M 10-Q · filed 2024-11-12 | $425.68M derived: sum of 3 quarters · filed 2025-05-29 | $580.18M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $7.48M 10-Q · filed 2024-08-09 | $217.81M derived: sum of 2 quarters · filed 2025-05-29 | $372.30M derived: sum of 3 quarters · filed 2025-05-29 | $364.96M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $210.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $364.83M derived: sum of 2 quarters · filed 2025-05-29 | $357.49M derived: sum of 3 quarters · filed 2025-05-29 | $499.46M 10-K · filed 2025-05-29 |
| 2022-12-31 | $154.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $147.15M derived: sum of 2 quarters · filed 2024-02-13 | $289.13M 10-Q · filed 2024-02-13 | $290.20M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$7.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $134.63M 10-Q · filed 2023-11-13 | $135.71M derived: sum of 3 quarters · filed 2023-11-13 | $127.28M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $141.98M 10-Q · filed 2023-08-14 | $143.05M derived: sum of 2 quarters · filed 2023-08-14 | $134.62M derived: sum of 3 quarters · filed 2023-08-14 | $438.56M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$7.35M derived: sum of 2 quarters · filed 2023-06-28 | $296.58M derived: sum of 3 quarters · filed 2023-06-28 | $306.79M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$8.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $295.51M derived: sum of 2 quarters · filed 2023-02-13 | $305.72M 10-Q · filed 2023-02-13 | $404.44M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $303.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $314.14M 10-Q · filed 2022-11-14 | $412.86M derived: sum of 3 quarters · filed 2022-11-14 | $413.32M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $10.21M 10-Q · filed 2022-08-15 | $108.92M derived: sum of 2 quarters · filed 2022-08-15 | $109.39M derived: sum of 3 quarters · filed 2022-08-15 | $285.34M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $98.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $99.18M derived: sum of 2 quarters · filed 2022-06-28 | $275.13M derived: sum of 3 quarters · filed 2022-06-28 | $456.26M 10-K · filed 2022-06-28 |
| 2020-12-31 | $464.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | $176.42M derived: sum of 2 quarters · filed 2022-02-14 | $357.55M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $175.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | $357.09M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $181.13M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |